• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 3:19:01 PM ET
    $ITMR
    Medical/Dental Instruments
    Health Care
    Get the next $ITMR alert in real time by email
    SC 13G/A 1 d27955dsc13ga.htm SC 13G AMENDMENT NO. 1 SC 13G Amendment No. 1

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

     

     

    Itamar Medical LTD.

    (Name of Issuer)

    Ordinary Shares, par value of NIS 0.01 per share

    (Title of Class of Securities)

    465437 10 1

    (CUSIP Number)

    October 27, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

     

     


    CUSIP No. 465437 10 1    Page 2 of 9

     

      1.    

      Name of reporting persons:

     

      MS PACE LP

      2.  

      Check the appropriate box if a member of a group:

      (a)  ☐        (b)  ☒

     

      3.  

      SEC use only:

     

      4.  

      Citizenship or place of organization:

     

      State of Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       5.     

      Sole voting power:

     

      28,317,403

       6.   

      Shared voting power:

     

      -0-

       7.   

      Sole dispositive power:

     

      28,317,403

       8.   

      Shared dispositive power:

     

      -0-

      9.    

      Aggregate amount beneficially owned by each reporting person:

     

      28,317,403 (see Item 4)

    10.  

      Check if the aggregate amount in Row (9) excludes certain shares

     

      ☐

    11.  

      Percent of class represented by amount in Row 9:

     

      6.7% (see item 4)

    12.  

      Type of reporting person:

     

      IV


    CUSIP No. 465437 10 1    Page 3 of 9

     

      1.    

      Name of reporting persons:

     

      MS PACE MANAGEMENT, LLC

      2.  

      Check the appropriate box if a member of a group:

      (a)  ☐        (b)  ☒

     

      3.  

      SEC use only:

     

      4.  

      Citizenship or place of organization:

     

      State of Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       5.     

      Sole voting power:

     

      0

       6.   

      Shared voting power:

     

      28,317,403

       7.   

      Sole dispositive power:

     

      0

       8.   

      Shared dispositive power:

     

      28,317,403

      9.    

      Aggregate amount beneficially owned by each reporting person:

     

      28,317,403 (see Item 4)

    10.  

      Check if the aggregate amount in Row (9) excludes certain shares

     

      ☐

    11.  

      Percent of class represented by amount in Row 9:

     

      6.7% (see item 4)

    12.  

      Type of reporting person:

     

      IV


    CUSIP No. 465437 10 1    Page 4 of 9

     

      1.    

      Name of reporting persons:

     

      SIGHTLINE MS GP, LLC

      2.  

      Check the appropriate box if a member of a group:

      (a)  ☐        (b)  ☒

     

      3.  

      SEC use only:

     

      4.  

      Citizenship or place of organization:

     

      State of Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       5.     

      Sole voting power:

     

      0

       6.   

      Shared voting power:

     

      28,317,403

       7.   

      Sole dispositive power:

     

      0

       8.   

      Shared dispositive power:

     

      28,317,403

      9.    

      Aggregate amount beneficially owned by each reporting person:

     

      28,317,403 (see Item 4)

    10.  

      Check if the aggregate amount in Row (9) excludes certain shares

     

      ☐

    11.  

      Percent of class represented by amount in Row 9:

     

      6.7% (see item 4)

    12.  

      Type of reporting person:

     

      IV


    CUSIP No. 465437 10 1    Page 5 of 9

     

    Item 1(a).

    Name of issuer:

    Itamar Medical Ltd.

     

    Item 1(b).

    Address of issuer’s principal executive offices:

    9 Halamish Street

    Caesarea 3088900, Israel

     

    Item 2(a).

    Names of person filing:

    MS PACE LP

     

    Item 2(b).

    Address of principal business office:

    8500 Normandale Lake Blvd, Suite 1070

    Bloomington, MN 55437

     

    Item 2(c).

    Citizenship:

    Citizenship is set forth in Row

    4 of the cover page for the Reporting Person and is incorporated herein by reference.

     

    Item 2(d).

    Title of class of securities:

    Ordinary Shares, par value of NIS 0.01 per share, of the Issuer.

     

    Item 2(e).

    CUSIP No.:

    465437 10 1

     

    Item 3.

    If this statement is filed pursuant to Secs. 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable


    CUSIP No. 465437 10 1    Page 6 of 9

     

    Item 4.

    Ownership

     

      (a)

    Amount beneficially owned: 28,317,403

      (b)

    Percent of class: 6.7% (see below)

      (c)

    Number of shares as to which the person has:

      (i)

    Sole power to vote or to direct the vote: 28,317,403

      (ii)

    Shared power to vote or to direct the vote: 28,317,403 MC Pace Management, LLC Sightline MS GP, LLC

      (iii)

    Sole power to dispose or to direct the disposition of: 28,317,403

      (iv)

    Shared power to dispose or to direct the disposition of: 28,317,403 MC Pace Management, LLC Sightline MS GP, LLC

    As of February 8, 2021, MS Pace LP (“MSP”), a Delaware limited partnership, and its controlling corporation, MS Pace Management, LLC, a Delaware limited liability company (“MSP Management”) and Sightline MS GP, LLC, a Delaware limited liability company (“Sightline,” and together with MSP and MSP Management, the “Reporting Persons”), beneficially owned 28,317,403 shares, or 6.7% based on 424,200,368 ordinary shares outstanding as of September 30, 2020.

    MSP Management as General Partner of MSP and its General Partner, Sightline, may be deemed to have the shared power to direct the disposition and vote of, and therefore to own the shares held by the Reporting Persons. Each of MSP Management and Sightline disclaim beneficial ownership of these securities, and this report shall not be deemed an admission that either MSP Management or Sightline is the beneficial owner of the securities for purposes of Section 13 or any other purpose.

     

    Item 5.

    Ownership of 5 percent or Less of a Class:

    Not Applicable.

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person:

    Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group:

    Not Applicable.


    CUSIP No. 465437 10 1    Page 7 of 9

     

    Item 9.

    Notice of Dissolution of Group:

    Not Applicable.

     

    Item 10.

    Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    CUSIP No. 465437 10 1    Page 8 of 9

     

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 12, 2021

     

    SIGHTLINE MS GP, LLC
    By:  

    /s/ Buzz Benson

    Name:   Name: Buzz Benson
    Title:   Title: Manager

     

    MS PACE MANAGEMENT, LLC
    By:  

    /s/ Buzz Benson

    Name:   Name: Buzz Benson
    Title:   Title: Manager

     

    MS PACE LP
    By:  

    /s/ Buzz Benson

    Name:   Name: Buzz Benson
    Title:   Title: Manager


    CUSIP No. 465437 10 1    Page 9 of 9

     

    EXHIBIT INDEX

     

    Exhibit
    No.

      

    Description

    A    Joint Filing Agreement (incorporated by reference to Schedule 13G filed July 31, 2019)
    Get the next $ITMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ITMR

    DatePrice TargetRatingAnalyst
    9/20/2021$30.00 → $31.00Outperform → Market Perform
    SVB Leerink
    9/15/2021$33.85Buy → Neutral
    Ladenburg Thalmann
    9/14/2021$36.00 → $31.00Buy → Neutral
    HC Wainwright & Co.
    9/14/2021$30.00 → $31.00Outperform → Market Perform
    Cowen & Co.
    More analyst ratings

    $ITMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Itamar Medical downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Itamar Medical from Outperform to Market Perform and set a new price target of $31.00 from $30.00 previously

      9/20/21 6:33:53 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical downgraded by Ladenburg Thalmann with a new price target

      Ladenburg Thalmann downgraded Itamar Medical from Buy to Neutral and set a new price target of $33.85

      9/15/21 7:36:23 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Itamar Medical from Buy to Neutral and set a new price target of $31.00 from $36.00 previously

      9/14/21 6:31:39 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    SEC Filings

    See more
    • SEC Form 15-12B filed by Itamar Medical Ltd.

      15-12B - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 6:02:01 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Itamar Medical Ltd.

      EFFECT - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 12:15:19 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Itamar Medical Ltd.

      EFFECT - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 12:15:09 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Financials

    Live finance-specific insights

    See more
    • Itamar Medical Reports Third Quarter 2021 Financial Results

      - Revenues Increased 23% Year-over-Year to $13.6 Million - - U.S. WatchPAT™ Revenues Increased 27% Year-over-Year to $11.3 Million - CAESAREA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the third quarter of 2021. "Third quarter results represent the strong traction our WatchPAT™ platform technology has gained entering the second half of 2021. Growth in the U.S. continues to outpace our overall growth on top of expanding adoption in the markets we serve thr

      11/18/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Reports Second Quarter 2021 Financial Results

      - Revenues Increased 41% Year-over-Year to $12.6 Million - - U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million - - Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the second quarter of 2021. "Our second quarter results demonstrated further growth as our WatchPAT™ technol

      8/10/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 10, 2021

      CAESAREA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its financial results for the second quarter 2021 before the U.S. market opens on Tuesday, August 10, 2021. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO. To listen live via webcast, please visit https://edge.media-server.com/mm

      7/28/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Itamar Medical Reports Third Quarter 2021 Financial Results

      - Revenues Increased 23% Year-over-Year to $13.6 Million - - U.S. WatchPAT™ Revenues Increased 27% Year-over-Year to $11.3 Million - CAESAREA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the third quarter of 2021. "Third quarter results represent the strong traction our WatchPAT™ platform technology has gained entering the second half of 2021. Growth in the U.S. continues to outpace our overall growth on top of expanding adoption in the markets we serve thr

      11/18/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors

      CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. Ortigas-Wedekind brings more than 30 years of medical technology and digital health experience including leadership roles in commercial and strategic marketing. She is currently the Chief Commercial Strategy Officer for Fogarty Innovation, a nonprofit organization in the medical technology space. In this role she is responsible for delivering commercial strategy gu

      8/12/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Reports Second Quarter 2021 Financial Results

      - Revenues Increased 41% Year-over-Year to $12.6 Million - - U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million - - Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the second quarter of 2021. "Our second quarter results demonstrated further growth as our WatchPAT™ technol

      8/10/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors

      CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. Ortigas-Wedekind brings more than 30 years of medical technology and digital health experience including leadership roles in commercial and strategic marketing. She is currently the Chief Commercial Strategy Officer for Fogarty Innovation, a nonprofit organization in the medical technology space. In this role she is responsible for delivering commercial strategy gu

      8/12/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Appoints Brad Fluegel to its Board of Directors

      CAESAREA, Israel, May 24, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Brad Fluegel to its Board of Directors. Mr. Fluegel's vast experience includes wide ranging leadership roles and 25+ years in the healthcare sector, primarily in strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for driving all commercial healthcare activities, including sales

      5/24/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Itamar Medical Ltd. (Amendment)

      SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)

      10/4/21 6:02:57 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Itamar Medical Ltd. (Amendment)

      SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)

      6/17/21 11:07:03 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Itamar Medical Ltd. (0001613170) (Subject)

      2/16/21 6:35:46 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care